Clinical Trials Browser

Interventional × Carcinoma, Neuroendocrine × lenvatinib × Clear all

NCT03290079 2025-12-22

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Phase 2 Completed

20 enrolled 12 charts

Carcinoma, Neuroendocrine, Neuroendocrine Tumors